Q-omics provides the consensus-scored KRT34 profile across patient tissues and cancer cell-line models. KRT34 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT34 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, KRT34 RNA expression shows 9,474 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUSC, and ESCA as cancer lineages where KRT34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT34 survival associations across molecular data types. KRT34 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT34 RNA expression–survival associations across cancer types. High KRT34 expression shows unfavorable associations in KIRC, MESO, COAD, LIHC, KIRP and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT34 RNA expression.
This table summarizes KRT34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT34 shows lower tumor expression in KICH and higher tumor expression in LUSC, BRCA, KIRP, BLCA and CHOL. The LUSC box plot shows higher KRT34 RNA expression in tumor versus normal tissue (log2 FC = +1.283, t-test p < 0.001).
This table shows molecular features associated with KRT34 in patient tissues and cancer cell lines. In patient samples, KRT34 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
